

To,

Date: 27.10.2012

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Dear Sir,

Sub: Outcome of board meeting held on 21.07.2012.

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of M/s Trimurthi Drugs & Pharmaceuticals Limited held on Saturday, 27.10.2012 at the registered office of the Company the following were duly considered and approved by the Board:

1. Un-audited financial results for the quarter ended 30.09.2012. (attached)
2. Limited Review Report for the quarter ended 30.09.2012. (attached)
3. Statement of assets and liabilities for the half year ended 30.09.2012.(attached)

Thanking you.

Yours faithfully,
For Trimurthi Drugs & Pharmaceuticals Limited

Arvind Kumar Bhangadia
Managing Director

Encl: as above

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER, 2012

Particulars	3 Months ended 30-09-2012	Preceding 3 months ended 30-06-2012	Corresponding 3 months ended 30-09-2011	Year to date figures for the current period ended 30-09-2012	Year to date figures for the current period ended 30-09-2011
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1. Net Sales / Income from Operations	140.46	155.82	133.29	296.28	452.84
2. Other Income	19.98	15.97	19.10	35.95	34.24
3. Total Income	160.45	171.79	152.39	332.23	487.08
4. Expenditure					
a. (Increase)/Decrease in stock in trade and work in Progress	21.80	(9.94)	15.91	11.86	22.20
b. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil
c. Purchase of Traded Goods	101.62	148.38	97.08	250.00	390.85
d. Employees Cost	4.66	5.48	7.23	10.14	12.76
e. Rent	1.59	1.77	1.77	3.36	3.45
f. Depreciation	6.68	6.56	12.05	13.24	12.05
g. Other Expenditure	5.52	5.30	2.81	10.82	10.99
Total	141.87	157.55	136.85	299.42	452.30
5. Interest	0.00	0.00	0.50	0.00	0.50
6. Exceptional Items	Nil	Nil	Nil	Nil	Nil
7. Profit/ (Loss) from Ordinary activities before tax (3) - (4+5+6)	18.58	14.24	15.04	32.81	34.28
8. Tax Expense (Including Deferred and Finge Benefit tax)	4.91	3.84	9.85	8.75	9.85
9. Net Profit/ (Loss) from Ordinary activities after Tax (7-8)	13.67	10.40	5.19	24.06	24.43
10. Extraordinary Items	Nil	Nil	Nil	Nil	Nil
11. Net Profit/ (Loss) for the period (9-10)	13.67	10.40	5.19	24.06	24.43
12. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	675.00	675.00	675.00	675.00	675.00
13. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	24.07	134.02	111.15	158.09	111.15
14. Earnings Per Share (EPS)					
a. Basic and diluted EPS before extraordinary items for the period, for the year to data and for the previous year (not to be annualised)	0.20	0.15	0.08	0.36	0.36
15. Public Share Holding					
- Number of Shares	2016200	2016200	2016200	2016200	2016200
- Percentage of shareholding	29.87%	29.87%	29.87%	29.87%	29.87%
16. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
a. Non encumbered					
- No of Equity Shares	4733800	4733800	4733800	4733800	4733800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	70.13%	70.13%	70.13%	70.13%	70.13%

For Trimurthi Drugs & Pharmaceuticals Ltd

Managing Director

Trimurthi Drugs & Pharmaceuticals Ltd.

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER, 2012


26

Particulars	Quarters ended			Half Years ended	
	30/09/2012	30/06/2012	30/09/2011	30/09/2012	30/09/2011
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1. Segment Revenue					
a. Pharma Business	143.78	156.10	135.84	299.88	456.77
b. Financial Services	19.66	15.69	16.55	35.35	30.31
c. Investments	25.80	0.00	0.00	25.80	50.54
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	189.24	171.79	152.39	361.03	537.62
2. Segment Profits					
a. Pharma Business	3.29	0.17	0.08	3.46	7.21
b. Financial Services	15.97	14.07	14.96	30.04	27.07
c. Investment in shares	0.00	0.00	0.00	0.00	0.00
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	19.26	14.24	15.04	33.50	34.28
3. Capital Employed					
a. Pharma Business	276.98	257.02	273.44	276.98	273.44
b. Financial Services	535.49	436.86	423.05	535.49	423.05
c. Investments	29.74	50.54	51.89	29.74	51.89
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	842.21	744.42	748.38	842.21	748.38

Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on 27/10/12.
- The financial results for the quarter ended 30-09-2012 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
- The status of investor grievances for the quarter ended 30-09-2012
 - pending at the beginning - Nil
 - received - 1
 - settled - 1
 - pending at the end - Nil

Place: Hyderabad,
Date : 27/10/12

for Trimurthi Drugs & Pharmaceuticals

 Managing Director